{"page":{"totalFilteredElements":65},"studies":[{"active":true,"description":"<div>A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive. A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer.</div>","eudractNumber":"2024-519773-19","id":11702,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"},{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06901531","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-16T11:09:29+02:00","shortTitle":"Lucerna","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)</div>","eudractNumber":null,"id":7962,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05578976","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-07-20T13:49:14+02:00","shortTitle":"M20-621","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Phase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma","eudractNumber":"2022-501810-77","id":8724,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06006117","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-17T09:09:16+02:00","shortTitle":"MARSUN","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study)</div>","eudractNumber":"2019-002264-27","id":8440,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"}],"nctNumber":"NCT04111978","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-03-06T13:49:03+01:00","shortTitle":"MATAO","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator&#8217;s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma","eudractNumber":"2023-510322-32","id":9816,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-02T08:44:40+02:00","shortTitle":"MERUS MCLA-158-CL02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma","eudractNumber":"2023-510323-30-00","id":9815,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06525220","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-10T14:21:22+02:00","shortTitle":"MERUS MCLA-158-CL03","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC<div><br /></div><div>AIO-PAK-0219<br /></div>","eudractNumber":"2023-503558-10-00","id":9825,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-07-26T14:03:02+02:00","shortTitle":"METAPANC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Klinische Pr&#252;fung der Phase III von CPX-351 zur Behandlung von Kindern mit Myeloischer Leuk&#228;mie mit Down-Syndrom 2018","eudractNumber":"2018-002988-25","id":8960,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-02-22T12:45:46+01:00","shortTitle":"ML-DS 2018","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A prospective randomized, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT)","eudractNumber":"2021-002864-36","id":10399,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT05429632","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-25T08:46:36+02:00","shortTitle":"MOTRANS - PKRPC001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","eudractNumber":"2021-002531-27","id":10386,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05243797","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-08-29T14:00:40+02:00","shortTitle":"MajesTEC-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]}]}